Background: Analysis of circulating cell-free DNA (cfDNA) is under intensive investigation for its potential to identify tumor somatic mutations. We have now explored the usefulness of such liquid biopsy testing with both the digital polymerase chain reaction (dPCR) and next-generation sequencing (NGS) during treatment of patients with the epidermal growth factor receptor (EGFR) inhibitor afatinib.
Introduction
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) show pronounced clinical activity in the treatment of individuals with non-small cell lung cancer (NSCLC) positive for activating mutations of EGFR [1] . Afatinib is a second-generation EGFR-TKI that irreversibly inhibits signaling by various dimers of the ErbB family of proteins including EGFR-ErbB1, HER2-ErbB2, ErbB3-ErbB3, and ErbB4-ErbB4. It has been found to prolong both overall survival and progression-free survival (PFS) in patients with lung adenocarcinoma harboring an exon 19 deletion (Ex19del) in EGFR compared with first-line platinum-based doublet chemotherapy [2] [3] [4] . Afatinib was also shown to prolong PFS in patients with EGFR mutation-positive NSCLC compared with the first-generation EGFR-TKI gefitinib [5] .
The analysis of circulating cell-free DNA (cfDNA) can be performed in a noninvasive and repetitive manner and can provide insight into the extent of intratumoral heterogeneity [6] . The isolation of cfDNA as a liquid biopsy thus offers a potential alternative to tissue biopsy for the detection of genetic alterations in various types of cancer [7] [8] [9] [10] . The low concentration of cfDNA necessitates the adoption of highly sensitive methods such as the digital polymerase chain reaction (dPCR) or nextgeneration sequencing (NGS) for its analysis. Both dPCR and NGS also allow quantitative evaluation of target molecules and are therefore applicable to monitoring of the dynamics of mutant alleles [7, 9, 10] . The detection limit of dPCR has been suggested to be lower than that of NGS [6] . On the other hand, dPCR is able to detect only specific genetic mutations, whereas NGS can detect multiple genetic alterations and is therefore potentially more suitable for the screening of patients for targeted therapy or for exploration of the mechanisms of resistance to anticancer drugs. A detailed comparison of these two techniques for the clinical analysis of cfDNA has not been described, however.
To investigate the usefulness of liquid biopsy testing during treatment of lung adenocarcinoma patients with afatinib, we have now undertaken a multicenter prospective study in which both dPCR and NGS were applied to the detection and quantitative monitoring of somatic mutations, including activating mutations of EGFR, in cfDNA.
Patients and methods

Study design and participants
Eligible patients were aged 20 years or older, were previously untreated with EGFR-TKIs, and had histologically and cytologically confirmed adenocarcinoma of the lung at stage IIIB or IV or postoperative recurrence and with a common activating mutation of EGFR (Ex19del or L858R point mutation). Additional eligibility criteria as well as assessment of efficacy and toxicity of afatinib treatment are described in Supplementary Material. All patients provided written informed consent, and the study was performed in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of each institution.
Sample collection and processing
Tumor samples were collected before treatment with afatinib. Blood samples (14 ml) were collected in tubes containing EDTA (disodium salt) both before (baseline) and during (4 and 24 weeks) afatinib treatment as well as after the development of progressive disease (PD). Detailed protocols for isolation of DNA from tumor samples and from blood samples (cfDNA) are provided in Supplementary Material.
Nanofluidic dPCR analysis
The principles and details of the nanofluidic dPCR system (BioMark HD System; Fluidigm, South San Francisco, CA) as performed with the Fluidigm digital chip have been described previously [11] . Further information is provided in Supplementary Material. 
Sequencing analysis
Results
Patient characteristics
Between 20 May and 25 November 2014, a total of 35 patients from 10 institutions across Japan were enrolled in the study and received at least one dose of afatinib. The baseline demographics and clinical characteristics of the subjects are shown in supple mentary Table S1 , available at Annals of Oncology online. Most patients had stage IV disease and were chemotherapy naïve. Fourteen (40.0%) patients had an L858R mutation and 21 (60.0 %) patients had an Ex19del of EGFR.
Antitumor activity and safety of afatinib treatment
Of the 35 patients enrolled in the study, 27 individuals (77.1%; 95% confidence interval [CI], 63.2-91.1%) showed a partial response and 31 (88.6%; 95% CI, 78.0-99.1%) achieved disease control. Afatinib reduced the size of the target lesions in 94.3% of all patients during the treatment period (supplementary Figure S1A , available at Annals of Oncology online). At a median follow-up time of 14.0 months, 21 (60.0%) patients had discontinued treatment as a result of PD (n ¼ 15, 42.9%), adverse events (n ¼ 5, 14.3%), or treatment refusal (n ¼ 1, 2.9%), whereas 14 (40.0%) patients were still receiving treatment with afatinib. Median PFS was 13.8 months (95% CI, 10.3 months to not achieved), with PFS for patients with an Ex19del being slightly longer than that for those with the L858R mutation of EGFR (median of 14.4 versus 10.8 months, P ¼ 0.22) (supple mentary Figures S1B and S2, available at Annals of Oncology online).
All 35 patients received afatinib at a starting dose of 40 mg/day, with 74.3% and 34.3% of patients requiring a dose reduction to 30 or 20 mg/day, respectively (supplementary Figure S3 , available at Annals of Oncology online). All adverse events leading to a dose reduction were due to nonhematologic toxicity, with the most common such events including diarrhea, rash or acne, stomatitis, and nail effect (supplementary Table S2 , available at Annals of Oncology online). The frequency of adverse events of grade 3 was lower than that previously reported [3, 4, 12] .
Detection of activating mutations of EGFR in cfDNA at baseline
The presence of activating mutations of EGFR in tumor DNA was confirmed by testing of available tumor samples from 32 patients by Scorpion ARMS (amplification-refractory mutation system) with the use of a Therascreen EGFR RGQ PCR Kit (Qiagen KK, Tokyo, Japan). The mean amount of cfDNA extracted per 1 ml of plasma at baseline for these 32 patients was 19.1 ng (supplemen tary Table S3 , available at Annals of Oncology online). Scorpion ARMS, dPCR, and NGS detected EGFR activating mutations in 59.4%, 81.3%, and 71.9% of baseline cfDNA samples, respectively. In 27 (84.4%) of the 32 patients, dPCR and NGS yielded concordant results for the detection of these mutations (kappa coefficient ¼ 0.570; 95% CI, 0.242-0.898). In most instances, discordance between dPCR and NGS results occurred when the amount of available cfDNA was low.
The allele frequency for EGFR activating mutations evaluated by NGS was significantly correlated with the number of alleles positive for these mutations evaluated by dPCR (Pearson's correlation coefficient ¼ 0.97, P < 0.001) (supplementary Figure S4 , available at Annals of Oncology online). The detection frequency for these mutations in cfDNA by dPCR was slightly higher for patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 1, with bone metastasis, with metastases in three or more organs, or with an M stage of M1b compared with those with a PS of 0, without bone metastasis, with metastases in less than three organs, or with an M stage of M1a, respectively ( Table 1 ). The total size of target lesions showed a weak but significant correlation with the copy number of alleles positive for EGFR activating mutations in cfDNA as evaluated by dPCR (Pearson's correlation coefficient ¼ 0.38; 95% CI, 0.02-0.64; P ¼ 0.03), with each 10-mm increase in the diameter of target lesions resulting in a 1.6-fold increase in copy number (supplemen tary Figure S5 , available at Annals of Oncology online).
Monitoring of EGFR activating mutations in cfDNA by dPCR
To investigate whether quantitative changes in EGFR mutant alleles in cfDNA reflect the response and development of resistance to treatment with afatinib, we monitored EGFR activating mutations in cfDNA at baseline, at 4 and 24 weeks after the onset of treatment, and after the development of PD using dPCR. Two patients discontinued treatment before 4 weeks (one because of PD and one because of an adverse event), six patients discontinued treatment between 4 and 24 weeks (four because of PD and two because of adverse events), and the remaining 24 patients were treated with afatinib for at least 24 weeks. As of follow-up at 24 weeks, cfDNA samples at baseline, 4 weeks, 24 weeks, and PD were thus available for 32, 30, 24, and 5 patients, respectively, with the corresponding detection frequency of EGFR activating mutations being 81.3% (26/32), 13.3% (4/30), 0% (0/24), and 100% (5/5) ( Figure 1A ). For five of the six patients with undetectable EGFR activating mutations in cfDNA at baseline, the mutations were also not detected in cfDNA at 4 and 24 weeks. All six patients with undetectable EGFR activating mutations in cfDNA at baseline were treated with afatinib for 24 weeks. Changes in the number of alleles positive for EGFR activating mutations in cfDNA for 25 of the 30 patients who were treated with afatinib for >4 weeks (excluding the five patients with mutations undetected in cfDNA at any time point) are shown in Figure 1B and C. The number of mutant alleles declined markedly at 4 weeks in 23 of these 25 patients. In the case of the 19 of these 25 patients who were treated with afatinib for 24 weeks, EGFR activating mutations were undetectable in cfDNA at 4 weeks in 17 (89.5%) patients or were detected at only a low copy number (<10 copies per milliliter) in the remaining two patients ( Figure 1B ). In the case of the four patients who experienced PD between 4 and 24 weeks, EGFR activating mutations were detected in cfDNA at a relatively high copy number (>10 copies per milliliter) at 4 weeks in 2 (50.0%) individuals ( Figure 1C ). Median PFS was slightly longer for the patients with undetectable EGFR activating mutations in cfDNA at baseline or 4 weeks than for those with detectable mutations at these time points (baseline, 14.4 versus 12.8 months, P ¼ 0.51; 4 weeks, 14.3 versus 10.0 months, P ¼ 0.52) (supplementary Figure S6 , available at Annals of Oncology online).
Detection of somatic mutations in tumor DNA and cfDNA by NGS
To examine the suitability of NGS for analysis of cfDNA, we subjected tumor DNA and cfDNA samples obtained from the 32 patients with both types of sample available to independent analysis with the Colon and Lung Cancer Panel v2, which targets 22 cancerrelated genes covered by 92 amplicons. A total of 45 mutations was identified in baseline tumor DNA (EGFR activating mutations in 32 [100%] patients, TP53 mutations in 11 [34.4%] patients, CTNNB1 mutations in 2 [6.3%] patients) (Figure 2A) , with a median number of mutations per patient of 1 (range, 1-2). Among the 45 mutations identified in baseline tumor DNA, 30 mutations were also detected in cfDNA whereas 15 were detected in tumor DNA but not in cfDNA, yielding a sensitivity of NGS for such analysis of cfDNA compared with that of tumor DNA of 66.7%.
Monitoring of somatic mutations in cfDNA by NGS
We also monitored somatic mutations including EGFR activating mutations in cfDNA by NGS at baseline, after 4 or 24 weeks of afatinib treatment, and after the development of PD. Somatic mutations other than EGFR activating mutations were detected in baseline cfDNA of eight patients. For these eight patients, the allele frequency for EGFR activating mutations and that for the other somatic mutations in cfDNA as evaluated by NGS changed concordantly during treatment ( Figure 2B-I) . The allele frequency for these somatic mutations in cfDNA determined by NGS also changed concordantly with the number of alleles positive for EGFR activating mutations in cfDNA evaluated by dPCR. The frequency of EGFR activating mutation detection in cfDNA by NGS at baseline, 4 weeks, 24 weeks, and PD was 71.9% (23/32), 13.3% (4/30), 0% (0/24), and 60% (3/5), respectively (supplementary Figure S7 , available at Annals of Oncology online).
Discussion
We have performed a multicenter prospective biomarker study of afatinib treatment for patients with lung adenocarcinoma positive for common EGFR mutations. As far as we are aware, this is the first prospective study to evaluate the application of liquid biopsy testing with both dPCR and NGS during treatment with an EGFR-TKI. The objective response rate for the study patients was 77.1% (95% CI, 63.2-91.1%) and the median PFS was 13.8 months (95% CI, 10.3 months to not achieved), with the median PFS for patients with an Ex19del being slightly better than that for those with the L858R mutation of EGFR (14.4 versus 10.8 months, P ¼ 0.22), consistent with previous results [3, 4, 12] . Although nonhematologic toxicities were common, the frequency of adverse events of grade 3 was lower than that previously reported [3, 4, 12] . Adoption of guidelines for the optimal management of adverse events and early dose reduction for afatinib may have prevented severe toxicities in the present study. The frequency of EGFR activating mutation detection in cfDNA at baseline and at the time of PD by dPCR was numerically higher than that determined by NGS (81.3% and 100% versus 71.9% and 60.0%, respectively). The detection frequency evaluated by dPCR in cfDNA at baseline was higher in patients at stage M1b than in those at M1a (24 of 28 [85.7%] for M1b versus 2 of 4 [50.0%] for M1a), consistent with previous results obtained with allele-specific PCR [13] . The total size of target lesions was also directly correlated with the copy number of alleles with EGFR activating mutations in cfDNA at baseline. These findings indicate that analysis of cfDNA by dPCR is able to identify EGFR activating mutations in patients with NSCLC, especially in those with extrapulmonary metastasis or a large tumor volume.
The number of alleles with EGFR activating mutations in cfDNA decreased rapidly and markedly after the initiation of afatinib treatment, with these mutations being detected in only 4 (13.3%) of 30 patients at 4 weeks and in 0 (0%) of 24 patients at 24 weeks. A large reduction in the size of target lesions induced by afatinib treatment may account for the marked decrease in the number of alleles with EGFR activating mutations in cfDNA to a level undetectable even by dPCR analysis. For patients who were treated with afatinib for 24 weeks, EGFR activating mutations were not detected or were detected at only a low copy number (<10 copies per milliliter) in cfDNA at 4 weeks. We found that median PFS was slightly better in patients for whom EGFR activating mutations in cfDNA were undetected at 4 weeks than in those for whom such mutations were detected (14.3 versus 10.0 months, P ¼ 0.52). Consistent with our findings, early tumor progression was previously observed in patients for whom erlotinib failed to clear EGFR activating mutations in cfDNA [14] , suggesting that the prediction of PFS based on monitoring of cfDNA is also applicable to treatment with first-generation EGFR-TKIs. Although a marked decrease in the size of target lesions is observed in most EGFR mutation-positive patients treated with EGFR-TKIs, PFS varies substantially among such individuals. Our present data suggest that monitoring of EGFR activating mutations in cfDNA has the potential to predict PFS for each patient treated with EGFR-TKIs. We found that NGS for the 22 genes covered by the Colon and Lung Cancer Panel v2 detected a median of 1 (range, 1-2) somatic mutation per patient in tumor DNA of NSCLC patients positive for EGFR activating mutations. The sensitivity of NGS with cfDNA versus that with tumor DNA for the detection of somatic mutations was 66.7%, consistent with previous findings [15] . The allele frequency for somatic mutations in cfDNA evaluated by NGS changed concordantly during afatinib treatment with the number of alleles positive for EGFR activating mutations determined by dPCR. These results indicate that NGS of cfDNA is reliable for the detection and monitoring of mutations in lung cancer, and that the application of NGS for the detection of somatic mutations in cfDNA may provide insight into the mechanisms of resistance to EGFR-TKI treatment. Furthermore, NGS of cfDNA shows potential for evaluation of tumor mutational load, which is predictive of the efficacy of immune checkpoint inhibitors in cancer patients [16] .
In conclusion, we found that afatinib showed good efficacy with tolerable toxicity in patients with lung adenocarcinoma positive for EGFR activating mutations. Our exploratory study also revealed that such mutations were detected in cfDNA more frequently by dPCR than by NGS. Monitoring of cfDNA by dPCR is informative for prediction of the efficacy of afatinib treatment. NGS detected various somatic mutations in cfDNA, and monitoring of cfDNA by NGS was found to be reliable. NGS is expected to become a more sensitive and inclusive tool in the future and has the potential to shed light on mechanisms of resistance to EGFR-TKIs.
